Qiagen NV (XTER:QIA) Cyclically Adjusted Revenue per Share: €9.14 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XTER:QIA Qiagen NV XTER:QIA
77 GF Score
Price €37.75
GF Value €42.59
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Qiagen NV Cyclically Adjusted Revenue per Share?

Qiagen NV XTER:QIA +1.10% 77 Cyclically Adjusted Revenue per Share is €9.14 as of Jun. 2026. GuruFocus rates XTER:QIA with a GF Score™ of 77/100 and a GF Value™ of €42.59 (Modestly Undervalued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Qiagen NV's adjusted revenue per share for the three months ended in Jun. 2026 was €2.235. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €9.14 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Qiagen NV's average Cyclically Adjusted Revenue Growth Rate was 4.90% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 4.40% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 7.30% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 6.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Qiagen NV was 15.50% per year. The lowest was 4.20% per year. And the median was 7.60% per year.

As of today (2026-08-28), Qiagen NV's current stock price is €37.75. Qiagen NV's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was €9.14. Qiagen NV's Cyclically Adjusted PS Ratio of today is 4.13.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Qiagen NV was 8.76. The lowest was 3.16. And the median was 5.78.


Qiagen NV  (XTER:QIA) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Qiagen NV's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=37.75/9.14
=4.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Qiagen NV was 8.76. The lowest was 3.16. And the median was 5.78.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Qiagen NV Cyclically Adjusted Revenue per Share Related Terms


Qiagen NV Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Qiagen NV's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Qiagen NV Cyclically Adjusted Revenue per Share Chart

Qiagen NV Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.03 8.50 8.42 9.47 8.87

Qiagen NV Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.55 8.65 8.87 9.06 9.14

XTER:QIA vs CRL, BLLN, TWST: Cyclically Adjusted Revenue per Share Comparison

For the Diagnostics & Research subindustry, Qiagen NV's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Qiagen NV Cyclically Adjusted PS Ratio vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Qiagen NV's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Qiagen NV's Cyclically Adjusted PS Ratio falls into.


XTER:QIA
77GF Score
Qiagen NV XTER:QIA
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Qiagen NV Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Qiagen NV's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=2.235/137.7700*137.7700
=2.235

Current CPI (Jun. 2026) = 137.7700.

Qiagen NV Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 1.408 100.570 1.929
201612 1.618 100.710 2.213
201703 1.367 101.440 1.857
201706 1.490 101.370 2.025
201709 1.465 102.030 1.978
201712 1.615 101.970 2.182
201803 1.337 102.470 1.798
201806 1.542 103.100 2.061
201809 1.537 103.950 2.037
201812 1.702 103.970 2.255
201903 1.474 105.370 1.927
201906 1.620 105.840 2.109
201909 1.712 106.700 2.211
201912 1.824 106.800 2.353
202003 1.619 106.850 2.088
202006 1.877 107.510 2.405
202009 1.944 107.880 2.483
202012 2.232 107.850 2.851
202103 2.289 108.870 2.897
202106 2.266 109.670 2.847
202109 2.186 110.790 2.718
202112 2.482 114.010 2.999
202203 2.767 119.460 3.191
202206 2.367 119.050 2.739
202209 2.448 126.890 2.658
202212 2.278 124.940 2.512
202303 2.194 124.720 2.424
202306 2.212 125.830 2.422
202309 2.158 127.160 2.338
202312 2.259 126.450 2.461
202403 2.017 128.580 2.161
202406 2.249 129.910 2.385
202409 2.185 131.610 2.287
202412 2.645 131.630 2.768
202503 2.138 133.330 2.209
202506 2.232 133.960 2.295
202509 2.186 135.920 2.216
202512 2.221 135.270 2.262
202603 2.038 136.910 2.051
202606 2.235 137.770 2.235

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €9.14 mean?
Qiagen NV (XTER:QIA) has a Cyclically Adjusted Revenue per Share of €9.14 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Qiagen NV and its competitors.
Is Qiagen NV's Cyclically Adjusted Revenue per Share too high?
Qiagen NV's current Cyclically Adjusted Revenue per Share is €9.14. Overall, Qiagen NV has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Qiagen NV's Cyclically Adjusted Revenue per Share compare to CRL and BLLN?
Qiagen NV's Cyclically Adjusted Revenue per Share of €9.14 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Diagnostics & Research company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Diagnostics & Research industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Qiagen NV and its competitors. Qiagen NV's current Cyclically Adjusted Revenue per Share is €9.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Qiagen NV stock overvalued right now?
Based on GuruFocus' analysis, Qiagen NV (XTER:QIA) is currently considered Modestly Undervalued. The stock's GF Value™ is €42.59, compared to a current price of €37.75 — trading 11.4% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is €9.14. Qiagen NV's overall GF Score™ is 77/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Qiagen NV (XTER:QIA), the current Cyclically Adjusted Revenue per Share is €9.14 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Qiagen NV (XTER:QIA) Overvalued in 2026?

Based on GuruFocus' analysis, Qiagen NV stock appears to be undervalued. The current stock price of €37.75 is trading 11.4% below its estimated GF Value™ of €42.59. GuruFocus considers Qiagen NV to be Modestly Undervalued.

Key valuation signals for XTER:QIA:

  • Cyclically Adjusted Revenue per Share: €9.14
  • GF Value™: €42.59 vs. price of €37.75 (11.4% below fair value)
  • GF Score™: 77/100 with 3 warning signs

No single metric tells the full story. See the XTER:QIA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Qiagen NV Business Description

Address Hulsterweg 82, Venlo, LI, NLD, 5912 PL
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).
77GF Score

Get the complete analysis for XTER:QIA

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€37.75
Price
€42.59
GF Value